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Abstract 
 
This study concerns the synthesis of 1-(2-ethoxyethyl)-4-oktynyl-4-hydroxypiperidine derivatives. The condensation of 1-(2-
ethoxyethyl)-4-oxopiperidine with 1-oktyne by modified Favorskii reaction gave 1-(2-ethoxyethyl)-4-oktynyl-4-
hydroxypiperidine. The structure of 4-alkynylpiperid-4-ol is in a good agreement with the results of elemental analysis and IR 
and 13C NMR spectral data. Acylation of hydroxyl group of obtained alcohol led to corresponding esters. To carry out the 
preliminary pharmacological study and to obtain the solid forms of new potentially biologically active piperidine derivatives 
their β-cyclodextrin complexes with β-cyclodextrin have been synthesized. The pharmacological activities of new compounds 
were predicted by PASS computer program. It has been found that 1-(2-ethoxyethyl)-4-oktynyl-4-acyloxypiperidines can 
exhibit anesthetic, anesthetic local, spasmolytic and immunosuppressory effects. The preliminary study of 1-(2-ethoxyethyl)-
4-(oktyn-1-yl)-4-propionyloxypiperidine (BIV-71) and 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-benzoyloxypiperidine (BIV-81) 
activities were carried out. It was shown that esters complexes possess a higher myelostimulatory activities compared with 
levamisole as standard. The acute toxicity of the β-cyclodextrin complexes is smaller than levamisole ones.  
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1. Introduction 
 
Immunomodulators can be effective agents for treating and preventing diseases and illnesses that stem from 
certain immunodeficiency and other depressed states of immunity. At present time the drugs inducing 
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myelosuppressive effects are widely used in medicine. They are all cytotoxic agents, which are applied in 
oncology practice (as a result of which a patient dies not because of cancer, but acute myelosuppression), anti-TB 
(antituberculosis) drugs (streptomycin, thioacetazone, isoniazid, p-aminosalicylic acid, diethylcarbamazine). 
Stoddard solvent (product of crude oil distillation), trinitrotoluene, pesticides chlorine, especially 
organochlorides, as lindane (J-hexachlorocyclohexane) and DDT (dichlorodiphenyltrichloroethane) cause 
pancytopenia (simultaneous decrease of the number of white blood cells, platelets, red blood cells) too. But the 
number of effective drugs able to produce blood cells and raise the peripheral blood and bone marrow myelogram 
in a short time is very limited. The most of them are represented by natural compounds from plants, animals and 
myelopeptides of bone marrow. Furthermore, myelostimulators are widely used in ophthalmology, surgery, 
cosmetics and biotechnology. Thereby, nowadays the search for synthetic myelostimulators is very topical.  
For the last years the search for compounds which stimulate the immune system has been carried out in the 
Lab. Medicinal Synthetic and Natural Compounds Chemistry of JSC “Institute of Chemical Sciences named after 
A.B. Bekturov”. The number of mono- and bicyclic N-alkoxyalkylpiperidines are known to possess significant 
pharmacological properties. The derivatives of N-alkoxyalkyl-4-alkynyl-4-hydroxypiperidine are well known for 
their analgesic, anesthetic, spasmolytic, and antibacterial activities1-3. 
 
2 Results and discussions 
 
Recently we have found that certain piperidine derivatives possess an immunomodulatory activity. In 
continuation of this work the synthesis and pharmacology of new 1-ethoxypropyl-4-oktynyl-4-acyloxypiperidines 
were carried out. The choice of these compounds is caused by the fact that the PASS computer program4,5 
predicts that they can exhibit anesthetic, anesthetic local, spasmolytic and immunosuppressory effects (Table 1). 
It is expected that in this group of compounds the propionic and benzoic ethers will possess the greatest activity.  
 
Table 1. Biological activity prediction for the 1-(2-ethoxyethyl)-4-oktynyl-4-acyloxypiperidines by PASS 
 
 
Compound Pa Pi Activity 
 
0.681 
0.483 
0.426 
0.373 
0.350 
0.328 
0.012 
0.012 
0.007 
0.059 
0.038 
0.099 
Spasmolytic, urinary 
Anesthetic 
Anesthetic local 
Spasmolytic 
Spasmolytic, Papaverin-like 
Immunosuppressant 
 
0.681 
0.530 
0.473 
0.460 
0.387 
0.316 
0,012 
0.009 
0.005 
0.036 
0.029 
0.106 
Spasmolytic, urinary 
Anesthetic 
Anesthetic local 
Spasmolytic 
Spasmolytic, Papaverin-like 
Immunosuppressant 
 
0,733 
0.665 
0.635 
0.614 
0.610 
0.008 
0.005 
0.012 
0.006 
0.004 
Spasmolytic, urinary 
Anesthetic 
Spasmolytic 
Spasmolytic, Papaverin-like 
Anesthetic local 
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This study is based on the principle that compounds similar in structure would exhibit similar properties6,7. 
And structural similarity plays an important role in modern approaches to predicting the properties of chemical 
compounds, designing substances with predefined biological properties. The goal of the present work is the 
determination of influence of alkynyl substituent length on pharmacological activity.  
The synthesis of 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-hydroxypiperidine 2 is based on condensation of one 
equivalent of 1-(2-ethoxyethyl)-4-oxopiperidine 1 to two moles of 1-oktyne in the presence of KOH by modified 
Favorskii reaction8. The reaction was carried out by stirring of reagent mixture at room temperature. The targeted 
alcohol 2 was obtained in a good yield. 
 
 
 
Fig.1. Synthesis of 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-hydroxypiperidine 2 
 
The structure of 4-alkynylpiperid-4-ol 2 is in a good agreement with the results of elemental analysis and 
spectral data. As synthesized 4-oktynylpiperidole has a relatively simple structure, its IR spectrum is simple, but 
it can serve as a reliable proof of its formation. In the spectrum of alcohol 2 the disappearance of the absorption 
band of the carbonyl group and the appearance of broad absorption band of hydroxyl groups at 3400 cm-1 and 
C{C bond absorption band of at 2235 cm-1 are proof the targeted product is obtained. 
 
13C NMR spectroscopy data are the most informative to determine the structure of compound 2. It should be 
noted that the presence of C{C singlets at 85.5 and 83.4 ppm and shielding of C3 and C5 signals (39.4 ppm) of 
piperidine cycle show the formation of desired product (Scheme).  
 
The corresponding esters 3, 4 were synthesized by the treatment of 1-(2-ethoxyethyl)-4-(oktyn-1-yl)piperidol 
2 with propionyl chloride and benzoyl chloride. In the IR spectra of esters 3, 4 there are observed an absorption 
bands of C=O (1743 cm-1) and C-O-C (1275 cm-1) confirming the presence of the ester group. 
 
Last step of potentially pharmacologically active compounds creating is preparing prodrugs. On this stage the 
compound was improved to become convenient for clinical use. To obtain the prodrugs the esters 3, 4 have been 
modified in a physiologically active compound. But the salts of esters with inorganic and organic acids, such as 
hydrochlorides, oxalates and succinates are oils. To obtain solid forms of drugs the inclusion complexes of 
potentially biologically active compounds with β-cyclodextrin (β-CD) have been synthesized. The inclusion of 
drug molecular in the cyclodextrin molecule have to improve its stability to light, temperature and oxidents, 
increase the solubility and bioavailability, mask odor and taste, reduce volatility. That all ultimately leads to 
increasing therapeutic efficacy9-11. β-Cyclodextrin complexes formation helped us to solve the problem of 
obtaining 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-acyloxypiperidines solid forms. 
Finally, a preliminary investigation of 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-propionyloxypiperidine (BIV-71) 
and 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-benzoyloxypiperidine (BIV-81) activities was carried out. To adverse 
immunosuppression effects the mice were administered with sodium cyclophosphamide. Critical decrease was 
observed in all subpopulations of blood. Blood analysis has revealed the number of red blood cells, platelet, and 
leukocytes significantly decreased. The treatment of cyclophosphamide had a negative effect on the bone marrow 
 Tynyshtyk K. Iskakova et al. /  Procedia Chemistry  10 ( 2014 )  358 – 363 361
 
either. On the background caused immunosuppression the preparations BIV-71 and BIV-81 were administrated 
to animals. Levamisole was used as control. According to our results which were carried in-vivo, complexes 
possess an immunomodulatory effect which exceeds the immunomodulatory effect of levamisole drug. 
 
The acute toxicities of the complexes are smaller than levamisole ones. Preliminary pharmacological studies 
showed higher myelostimulator activities of esters 3, 4 inclusion complexes, compared with levamisole. Both 
forms of the drug showed comparable potent in vivo myelostimulatory activity (p>0.05) and this fact indicates a 
good availability of the drug in aqueous medium by incorporating the drug into CD cavity.  
 
The results suggest that including an oktynyl group in 1-(2-ethoxyethyl)-4-oxypiperidine molecule clearly 
improves its myelostimulatory effect and both BIV-71 and BIV-81 may be as useful as myelostimulators, but 
more pharmacological investigations are needed in order to establish its activity spectrums.  
 
3. Conclusion 
 
The search for novel non-toxic immunomodulators has become an important goal of research of chemistry and 
medicine. It is known that 4-alkynylpiperidine derivatives stimulate the immune system. To obtain new 
myelostimulators the synthesis of 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-hydroxypiperidine and following acylation 
of forming product were carried out. To convert liquid form of 1-(2-ethoxyethyl)-4-(oktyn-1-yl)-4-
acyloxypiperidines into the solid state β-cyclodextrin complexes were synthesized. The prediction of biological 
activity of ethers made by PASS differs from preliminary test data. According to the forecast the propionic ester 
should possess an immunosuppressory activity. The pharmacological study showed that myelostimulatory 
activity of 4-hydroxypiperidine molecular depends on alkynyl substitutent length. Furthermore, the acute 
toxicities of the complexes are smaller than levamisole ones. 
 
4. Experimental  
 
NMR spectra were recorded on JNM-ECA 400 «JEOL» (400 and 100.8 MHz) in CDCl3, with TMS as an 
internal standard. IR spectra were recorded on a «Thermo Еlectron Corporation» Spectrometer «Nicolet 5700» 
(KBr). The purity of obtained compounds was checked by TLC on alumina with benzene–isopropanol as eluent; 
spots were visualized with iodine vapors. 
 
Synthesis of 1-(2-ethoxyethyl)-4-(octyn-1-yl)piperidin-4-ol 2. Dioxane solution of 5.0 g (0.0292 M) 1-(2-
ethoxyethyl)piperidin-4-one 1 was added to a mixture of 3.27 g (58.4 mmol) of powdered technical KOH and 
6.42 g (58.4 mmol) of 1-octyne. After completion of the reaction (TLC analysis) 4.9 ml of water was added. The 
product was treated by diethyl ether and aqueous layer was extracted with benzene. The combined organic layers 
were washed with 10% HCl. To remove the neutral products aqueous layer was extracted with benzene, and then 
basified with saturated NaOH solution. The solvent was evaporated. 7.76 g (95%) of crude 1-(2-ethoxyethyl)-4-
(octyn-1-yl)piperidin-4-ol 2 was obtained. Distillation of product under reduced pressure led to a pale yellow oil 
(b.p. 153-155qC/ 1 mm Hg, nD20 1.4803). 
 
IR (film)Q, cm-1: 1117 (COC), 2238 (C{C), 3400 (OH). 
13C NMR (CDCl3) G, ppm: 14.1 (CH3 heptyn), 15.2 (CH3 ethoxy), 18.7, 28.7, 28.6, 31.3, 22.6 
({CCH2CH2CH2CH2); 39.4 [C(3,5)], 51.0 [C(2,6)]; 57.6 (NCH2CH2O); 66.5 (OCH2CH3); 68.4 [CH2CH2O].  
Anal. calc. for C17H31NO2: C, 72.59; H, 11.03; N, 4.98. 
Found: C, 72.54; H, 11.00; N, 4.91.  
 
Synthesis of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-propionyloxypiperidine 3. 4.44 g (34.2 mmol) of propionic 
anhydride and 3.16 g (34.2 mmol) of propionyl chloride were added to 0.96 g (3.4 mmol) of 1-(2-ethoxyethyl)-4-
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(octyn-1-yl) piperidin-4-ol. The excess of reagents was removed. The resulting oil was dissolved in water and 
then treated with potassium carbonate. 0.70 g (62%) of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-
propionyloxypiperidine 3 (nD20 1.4684) were obtained.  
IR (film) Q, cm-1: 1117  (COC), 1274 (OC ether); 1740 (C=O), 2236 (C{C). 
Anal. calc. for C20H35NO3: C, 71.22; H, 10.38; N, 4.15. 
Found: C, 71.30; H, 10.31; N, 4.17. 
 
Synthesis of cyclodextrin complex of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-propionyloxypiperidine. The 
solution of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-propionyloxypiperidine 3 in 30 ml ethanol was added to and 2.41 
g (1.7 mmol) β-cyclodextrin in 90 ml water. The water and ethanol were removed at 5055°C. 2.68 g (89.6%) 
and cyclodextrin complex of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-propionyloxypiperidine was obtained as white 
powder, decomposed above 240°C. 
Anal. calc. for C62H105NO38: C, 42.71; H, 7.73; N, 0.95. 
Found: C, 42.73; H, 7.75; N, 0.89. 
 
Synthesis of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-benzoyloxypiperidine 4. 1.22 g (4.3 mmol) of benzoyl 
chloride was added to 0.61 g (4.3 mmol) of 1-(2-ethoxyethyl)-4-(octyn-1-yl)piperidin-4-ol 2. The mixture was 
hold at room temperature, then the resulting oil was treated by water and potassium carbonate. The c product was 
extracted with benzene, dried over MgSO4 and the solution was concentrated. 1.43 g (86%) of 1-(2-ethoxyethyl)-
4-(octyn-1-yl)-4-benzoyloxypiperidine 4 (nD20 1.5096) was obtained. 
IR (film) Q, cm-1: 1111  (COC), 1275 (OC ether); 1726 (C=O), 2247 (C{C). 
Anal. calc. for C24H35NO3: C, 74.80; H, 9.09; N, 3.64. 
Found: C, 74.82; H, 9.06; N, 3.67. 
 
Synthesis of cyclodextrin complex of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-benzoyloxypiperidine. The 
solution of 1.17 g (3.0 mmol) of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-benzoyloxypiperidine 4 in 30 ml ethanol was 
added to and 4.27 g (3.0 mmol ) β-cyclodextrin in 90 ml water. The water and ethanol were removed at 5055°C 
and 5.10 g (94%) of cyclodextrin complex of 1-(2-ethoxyethyl)-4-(octyn-1-yl)-4-benzoyloxypiperidine was 
obtained as white powder, decomposed above 240°C. 
Anal. calc. for C66H105NO38: C, 44.27; H, 7.55; N, 0.92. 
Found: C, 44.25; H, 7.56; N, 0.93. 
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